UNSPSC 51112306: Treosulfan

This classification denotes an alkylsulfonate compound with the molecular formula C6H14O8S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CO61ER3EPI, chemically known as 1,2,3,4-butanetetrol, 1,4-dimethanesulfonate, (s-(r*,r*))- (9ci) but more generally known as treosulfan, which bears US NIH Compound Identifier 9296. European Medicines Agency schedules Treosulfan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11235MIG.

UNSPSC 51112306 Treosulfan, a Commodity code, covers pharmaceutical procurement activity in state and local health systems and benefit programs — specifically in this case, sourcing of specialty oncology drugs through direct-to-manufacturer channels rather than traditional pharmacy benefit manager or group purchasing organization intermediaries. State and local governments buy treosulfan and related chemotherapy agents through health department pharmacy programs, state employee and retiree health benefit plans, and Medicaid agencies. The recent activity under this code reflects a broader shift toward value-based purchasing models and direct contracting arrangements that allow states to negotiate net pricing and outcomes-based agreements with manufacturers, reducing reliance on traditional PBM and GPO networks for specialty pharmaceutical access.

The Texas Health and Human Services Commission issued a Request for Information (RFI No. HHS0017013) on April 3, 2026, to gather vendor capabilities regarding a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. The RFI seeks detailed information from potential vendors about experience with direct contracting for self-insured employers and health plans, flexibility to negotiate contracts based on negotiated net pricing models without rebates, and capability to implement value-based or outcomes-based agreements. No award value or budget was identified at this RFI stage, as the state was conducting foundational research to inform future formal solicitation strategy. The RFI represents an exploratory procurement mechanism rather than a competitive solicitation with binding timelines or evaluation criteria. Activity under this code appears limited to recent state Medicaid and employee health benefit program initiatives focused on specialty drug access optimization; no broader geographic clustering of treosulfan procurement across multiple states or jurisdictions is evident from the available record.